Publications by authors named "Kazuhiko Nakagawa"

100Publications

The patient's perspective on treatment with dacomitinib: patient-reported outcomes from the Phase III trial ARCHER 1050.

Future Oncol 2020 Nov 9. Epub 2020 Nov 9.

State Key Laboratory of Translational Oncology, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2020-0888DOI Listing
November 2020

Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC.

J Thorac Oncol 2020 Oct 20. Epub 2020 Oct 20.

Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2020.10.006DOI Listing
October 2020

Extraperitoneal colostomy in robotic surgery for rectal cancer using a tip-up fenestrated grasper.

Asian J Endosc Surg 2020 Oct 20. Epub 2020 Oct 20.

Department of Surgery, Sumitomo Besshi Hospital, Niihama-shi, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ases.12880DOI Listing
October 2020

Syncope Caused by a Giant Mass Occupying the Hemithorax.

Ann Thorac Surg 2020 Sep 24. Epub 2020 Sep 24.

Department of Thoracic Surgery, Japanese Red Cross Ashikaga Hospital. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.athoracsur.2020.06.142DOI Listing
September 2020

Simultaneous targeting of MET overexpression in mutation-positive non-small cell lung cancer can increase the benefit of EGFR-TKI therapy?

Transl Lung Cancer Res 2020 Aug;9(4):1617-1622

Department of Medical Oncology, Kindai University, Faculty of Medicine, 377-2 Ohno-higashi, Osaka-Sayama, Osaka 589-8511, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tlcr-20-707DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481636PMC
August 2020

A Case of Pulmonary Tumor Thrombotic Microangiopathy Suggested by the Presence of Tumor Cells in Peripheral Blood.

Case Rep Oncol 2020 May-Aug;13(2):843-848. Epub 2020 Jul 14.

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000508362DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443647PMC
July 2020

Long-term response to ipilimumab after nivolumab failure in a case of anorectal melanoma with an intermediate tumor mutation burden and negative for PD-L1 expression.

Mol Clin Oncol 2020 Aug 21;13(2):175-178. Epub 2020 May 21.

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka 589-8511, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/mco.2020.2048DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366236PMC
August 2020

Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer.

Cancer Chemother Pharmacol 2020 Aug 8;86(2):211-219. Epub 2020 Jul 8.

Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osakasayama City, Osaka, 5898511, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-020-04112-1DOI Listing
August 2020

Association of immune-related adverse events with immune checkpoint inhibitor efficacy: real or imaginary?

BMC Med 2020 04 21;18(1):111. Epub 2020 Apr 21.

Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohno-higashi, Osakasayama, Osaka, 589-8511, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12916-020-01583-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171785PMC
April 2020

Psychosocial effects of appearance changes due to cancer treatment and needs for information and supportive care in Japanese cancer patients.

Asia Pac J Clin Oncol 2020 Oct 14;16(5):e185-e191. Epub 2020 Apr 14.

Department of Medical Oncology, Kindai University Faculty of Medicine, Ōsakasayama, Osaka, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13333DOI Listing
October 2020

Severe Immune-Related Hepatitis Treated With Plasma Exchange.

J Thorac Oncol 2020 03;15(3):e39-e42

Department of Medical Oncology, Faculty of Medicine, Kindai University, Osaka-Sayama, Osaka, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.11.014DOI Listing
March 2020

A first attempt to establish a definition of oligometastatic non-small cell lung cancer by a European consensus group.

J Thorac Dis 2019 Dec;11(12):5635-5642

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2019.11.49DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988020PMC
December 2019

Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer.

Eur J Cancer 2020 01 12;125:49-57. Epub 2019 Dec 12.

Department of Oncology, University of Turin, Azienda Ospedaliero-Universitaria San Luigi Gonzaga, Turin, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2019.11.006DOI Listing
January 2020

Combination therapy with PD-1 or PD-L1 inhibitors for cancer.

Int J Clin Oncol 2020 May 23;25(5):818-830. Epub 2019 Sep 23.

Department of Medical Oncology, Faculty of Medicine, Kindai University, 377-2 Ohno-higashi, Osaka-Sayama, Osaka, 589-8511, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-019-01548-1DOI Listing
May 2020

Clinical and immune profiling for cancer of unknown primary site.

J Immunother Cancer 2019 09 13;7(1):251. Epub 2019 Sep 13.

Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohno-higashi, Osaka-Sayama, Osaka, 589-8511, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0720-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6743146PMC
September 2019

Successful long-term treatment of non-small cell lung cancer positive for rearrangement with pemetrexed.

Onco Targets Ther 2019 8;12:5355-5358. Epub 2019 Jul 8.

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka 589-8511, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S211582DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6625745PMC
July 2019

Effects of dose modifications on the safety and efficacy of dacomitinib for mutation-positive non-small-cell lung cancer.

Future Oncol 2019 Aug 17;15(24):2795-2805. Epub 2019 Jul 17.

Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, 510080, PR China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2019-0299DOI Listing
August 2019

A Case of Metastatic Malignant Breast Adenomyoepithelioma With a Codon-61 Mutation of HRAS.

Clin Breast Cancer 2019 10 20;19(5):e589-e592. Epub 2019 Jun 20.

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.05.001DOI Listing
October 2019

Reply to A.-M. Conway et al.

J Clin Oncol 2019 08 18;37(23):2090. Epub 2019 Jun 18.

Hidetoshi Hayashi, MD, PhD; Kazuto Nishio, PhD; and Kazuhiko Nakagawa, MD, Kindai University, Osaka-Sayama, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.00767DOI Listing
August 2019

New Era for Next-Generation Sequencing in Japan.

Cancers (Basel) 2019 May 28;11(6). Epub 2019 May 28.

Department of Genome Biology, Kindai University Faculty of Medicine, 377-2 Ohno-higashi, Osaka-Sayama, Osaka 589-8511, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11060742DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627271PMC
May 2019

[fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification.

Int J Cancer 2019 12 24;145(12):3414-3424. Epub 2019 May 24.

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.32408DOI Listing
December 2019

Management of common adverse events related to first-line dacomitinib use in mutation-positive non-small-cell lung cancer: a pooled safety analysis.

Future Oncol 2019 May 6;15(13):1481-1491. Epub 2019 Mar 6.

State Key Laboratory of South China, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, PR China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0944DOI Listing
May 2019

Safety and Efficacy of Alectinib in a Patient With Advanced NSCLC Undergoing Hemodialysis.

J Thorac Oncol 2019 03;14(3):e50-e52

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.11.012DOI Listing
March 2019

A Phase II Study of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer who Responded to Prior PD-1/L1 Inhibitors: West Japan Oncology Group 9616L (WJOG9616L).

Clin Lung Cancer 2019 03 11;20(2):139-141. Epub 2018 Dec 11.

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.12.001DOI Listing
March 2019

First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive Mutation-Positive Non-Small Cell Lung Cancer?

Int J Mol Sci 2019 Jan 3;20(1). Epub 2019 Jan 3.

Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohno-higashi, Osaka-Sayama, Osaka 589-8511, Japan.

View Article

Download full-text PDF

Source
http://www.mdpi.com/1422-0067/20/1/146
Publisher Site
http://dx.doi.org/10.3390/ijms20010146DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6337322PMC
January 2019

Gankyrin Contributes to Tumorigenesis and Chemoresistance in Sporadic Colorectal Cancer.

Digestion 2019 4;100(3):192-200. Epub 2018 Dec 4.

Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000494969DOI Listing
February 2020

Dual blockade of EGFR tyrosine kinase using osimertinib and afatinib eradicates EGFR‑mutant Ba/F3 cells.

Oncol Rep 2019 Feb 22;41(2):1059-1066. Epub 2018 Nov 22.

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka‑Sayama, Osaka 589‑8511, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/or.2018.6881DOI Listing
February 2019

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

J Clin Oncol 2018 Aug 28:JCO2018783118. Epub 2018 Aug 28.

Thanyanan Reungwetwattana, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Kazuhiko Nakagawa, Kindai University School of Medicine, Osaka; Naoyuki Nogami, National Hospital Organization Shikoku Cancer Center, Matsuyama; Isamu Okamoto, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Byoung Chul Cho, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul; Eun Kyung Cho, Gachon University Gil Medical Center, Incheon; Ki Hyeong Lee, Chungbuk National University Hospital, Cheong-ju, Republic of Korea; Manuel Cobo, Institute of Biomedical Research in Málaga, Málaga University Hospital Regional, Málaga, Spain; Alessandro Bertolini, Hospital of Sondrio, Sondrio, Italy; Sabine Bohnet, Universitätsklinik Schleswig-Holstein, Lübeck, Germany; Caicun Zhou, Pulmonary Hospital of Tongji University, Shanghai, People's Republic of China; Natasha Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Rachel Hodge, Astrid McKeown, Andrew P. Brown, and Yuri Rukazenkov, AstraZeneca, Cambridge, United Kingdom; Suresh S. Ramalingam, Winship Cancer Institute, Emory University, Atlanta, GA; and Johan Vansteenkiste, University Hospital, Katholieke Universiteit Leuven, Leuven, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.3118DOI Listing
August 2018

Nivolumab-Induced Hemophilia A Presenting as Gastric Ulcer Bleeding in a Patient With NSCLC.

J Thorac Oncol 2018 12 12;13(12):e239-e241. Epub 2018 Jul 12.

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.06.024DOI Listing
December 2018

An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors.

Cancer Chemother Pharmacol 2018 09 10;82(3):511-519. Epub 2018 Jul 10.

Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka, 589-8511, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-018-3618-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105164PMC
September 2018

Induction Chemoradiotherapy (50 Gy), Followed by Resection, for Stage IIIA-N2 Non-Small Cell Lung Cancer.

Ann Thorac Surg 2018 10 8;106(4):1018-1024. Epub 2018 Jun 8.

Department of Thoracic Surgery, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.athoracsur.2018.05.027DOI Listing
October 2018

Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.

J Clin Oncol 2018 08 4;36(22):2244-2250. Epub 2018 Jun 4.

Tony S. Mok, State Key Laboratory of South China, Chinese University of Hong Kong, Hong Kong; Ying Cheng, Jilin Provincial Cancer Hospital, Changchun; Xiangdong Zhou, First Affiliated Hospital of Third Military Medical University, Chongqing; Yi-Long Wu, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China; Ki Hyeong Lee, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea; Kazuhiko Nakagawa, Kindai University Hospital, Osaka; Seiji Niho, National Cancer Center Hospital East, Kashiwa, Japan; Min Lee, SFJ Asia Pacific, Singapore; Rolf Linke, SFJ Pharmaceuticals Group, Pleasanton, CA; Rafael Rosell, Catalan Institute of Oncology, Barcelona; Jesus Corral, Hospital Universitario Virgen del Rocio, Seville, Spain; Maria Rita Migliorino, Pulmonary Oncology Unit, San Camillo-Forlanini Hospital, Rome, Italy; Adam Pluzanski, The Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland; Eric I. Sbar, Pfizer, Collegeville, PA; Tao Wang and Jane Liang White, Pfizer, Groton, CT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.7994DOI Listing
August 2018